JiscMail Logo
Email discussion lists for the UK Education and Research communities

Help for GP-UK Archives


GP-UK Archives

GP-UK Archives


GP-UK@JISCMAIL.AC.UK


View:

Message:

[

First

|

Previous

|

Next

|

Last

]

By Topic:

[

First

|

Previous

|

Next

|

Last

]

By Author:

[

First

|

Previous

|

Next

|

Last

]

Font:

Proportional Font

LISTSERV Archives

LISTSERV Archives

GP-UK Home

GP-UK Home

GP-UK  1998

GP-UK 1998

Options

Subscribe or Unsubscribe

Subscribe or Unsubscribe

Log In

Log In

Get Password

Get Password

Subject:

Creutzfeldt-Jakob Disease and General Practitioners

From:

[log in to unmask]

Reply-To:

[log in to unmask]

Date:

Sun, 7 Jun 1998 18:18:47 EDT

Content-Type:

text/plain

Parts/Attachments:

Parts/Attachments

text/plain (139 lines)

Patients with Creutzfeldt-Jakob Disease are often first seen by their general
practitioners.  Creutzfeldt-Jakob Disease (CJD) has greater public health
consequences than the mere number of reported case might lead one to believe
because it is not a reportable disease in most places, is often misdiagnosed,
is infectious and is not killed by normal sterilization.  CJD is a horrendious
infectious fatal brain-deteriorating disease for which there is no treatment
or cure.  It is caused by a prion. One strain of CJD is linked to bovine
spongiform encephalopathy (i.e. Mad Cow Disease) in England.

Throughout the world people get CJD through 3 means: familial (genetic),
sporadic (don't know how) and iatrogenic (through a medical procedure such as
human pitutitary growth hormones, human gonadotrophin fertility treatments,
contaminated surgical equipment and dura mater and cornea transplants.)   CJD
can take decades after exposure for the patient to show symptoms.  However,
once a person shows symptoms their decline is rapid and they die within a year
of first showing symptoms.

CJD should be considered whenever a patient develops a rapid dementia and
myoclonus. The initial symptoms are subtle and ambiguous and include insomnia,
depression, confusion, personality and behavioral changes, strange physical
sensations, and  memory, coordination and visual problems.  Rapidly
progressive dementia and usually myoclonus (involuntary, irregular jerking
movements) develop as CJD progresses.  Also,  language, sight, muscular
weakness, and coordination problems worsen. The patient may appear startled
and become rigid. In the final stage the patient loses all mental and physical
functions. The patient may lapse into a coma and usually dies from an
infection like pneumonia precipitated by the bedridden, unconscious state. The
duration of CJD from the onset of symptoms to death is usually one year of
less.  A 14-3-3 spinal fluid test is over 95% effective in diagnosing CJD when
symptoms are present.  (For information on the test contact Dr  Clarence
Joseph Gibbs, Jr.; National Institutes of Health, (30l) 496-4821 or 6321.)
CJD patients often die at home and therefore have home health service and have
family members as caregivers.

Since early signs of CJD are often psychological, victims will often receive
psychological treatment.  In addition, people, including school-age children
of Creutzfeldt-Jakob Disease victims who die in their 40s, often require
counseling to deal with the death.  And, then there's the recipients of
medical treatments such as human pituitary growth hormones and dura mater
transplants who are at high risk of CJD and the people with a genetic mutation
for familial CJD who must live with CJD hangiing over their heads.  Another
group includes people who receive withdrawal notices that the blood they or,
worst yet, their children, received came from a pool which included a donor
that died of CJD.  While the question of whether CJD is passed through blood
products is yet to be resolved, receiving this type of notice causes great
anxiety in people.  

CJD is more common than reported.  In one study of Alzheimer patients 13% when
autopsied were found to really have CJD.

Also, since normal sterilization methods do no kill the CJD infectious agent
and , it can therefore be spread by surgical instruments, it is more of a
danger to public health than mere number of cases would suggest..

Whether CJD is spread by human blood is controversial,.  Pooled blood products
are withdrawn as a precaution if it is found after the product has been
released that a person in the donor pool has died of CJD of is at higher risk
of contracting CJD.  However, by this point it has often already been used in
humans.  While the controversy remains as to whether CJD can be passed through
blood products, blood products continue to be used in vaccines such as rabies
and allergy shots; in InVitro Fertilization (IVF) cultures; and in medical
test fluids.  At the end of this e-mail I have included the U. S.
Congressional Mandate requesting the Centers for Disease Control to conduct a
study to assess whether the CJD infectious agent is spread through blood
products.

CJD Voice is an e-mail discussion group.  Most members have lost a loved one
to CJD or currently have a loved one with CJD.  Other members include people
who took human pituitary growth hormones as children and therefore are at
higher risk of getting CJD and people who received notices that the blood
products their children received were from a pool that included a person who
died from CJD.  It provides support to these people as well as tries to
increase funding for CJD research so treatments and a cure can be found.  The
CJD webpage has a message board, chat room, links to other websites with CJD
information and a list of CJD researchers accepting financial contributions.

The address for the CJD Voice Webpage is
http://members.aol.com/larmstr853/cjdvoice/cjdvoice.htm
Please feel free to visit the website and to refer other people to it.

Feel free to distribute this information to whomever you choose.

[log in to unmask]



 The Centers for Disease Control and Prevention (CDC) Creutzfeldt-Jakob
     Disease Program

     A Congressional Mandate

     In response to concerns that CJD may be transmitted through blood or
     blood products, the U.S. Congress requested that the
     CDC conduct a study to assess whether CJD is a threat to the safety of
     the nation's blood supply. Researchers believe that
     the risk of transmission to humans through blood products is very
     small since there have been no known cases of CJD
     contracted by humans in this manner. However, precautions are being
     taken to assure that the blood supply is safe from this
     infectious agent. Current blood safety policy requires that any blood
     products made from blood donated by a person who
     later develops CJD, or is found to have risk factors for CJD, must be
     withdrawn. Until the question of transmissibility is
     resolved, the availability and the price of blood products will
     continue to be adversely impacted by shortages caused by
     recalls and the destruction of blood products which, to date, has cost
     over $100 million.

     The Program: How You Can Help

     Because the signs and symptoms of CJD may not develop for up to 30
     years, a person could be infected and not show any
     symptoms during his or her lifetime. Furthermore, there is no
     screening test available for CJD and the only sure way to test
     for CJD is by analyzing brain tissue after death. The CJD program asks
     families of individuals who have received blood
     products to donate brain tissue after their death. The brain tissue
     will be shipped to Stephen J. Armond, M.D., Ph.D.,
     Professor of Neuropathology, University of California, San Francisco
     to test for evidence of CJD. Other brain tissue will be
     stored at CDC in Atlanta for analysis in the future when more is known
     about the cause of CJD.

     Participation in the CJD program is voluntary. The CDC is aware that
     the death of a family member is a difficult time to make
     important decisions. Therefore, the CDC is working through your
     regional coordinator, physician, and treatment center staff to
     provide support to you and your family as you discuss brain tissue
     donation. To help with making an informed and rational
     decision, the CDC has developed information packets which answer
     commonly asked questions about the program including:
     how to authorize the donation; how confidentiality will be assured;
     the ability to retrieve the brain tissue without disfigurement
     and without affecting funeral arrangements; and the time frame for
     receiving test results.


%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%

Top of Message | Previous Page | Permalink

JiscMail Tools


RSS Feeds and Sharing


Advanced Options


Archives

March 2024
October 2023
August 2023
June 2023
May 2023
February 2023
June 2022
October 2021
January 2021
October 2020
September 2020
August 2020
July 2020
June 2020
March 2020
January 2020
December 2019
September 2019
July 2019
June 2019
May 2019
March 2019
February 2019
January 2019
September 2018
August 2018
July 2018
June 2018
May 2018
April 2018
March 2018
January 2018
December 2017
November 2017
October 2017
September 2017
August 2017
July 2017
June 2017
May 2017
March 2017
January 2017
December 2016
November 2016
October 2016
September 2016
August 2016
July 2016
June 2016
May 2016
April 2016
March 2016
February 2016
January 2016
December 2015
November 2015
October 2015
September 2015
August 2015
July 2015
June 2015
May 2015
April 2015
March 2015
February 2015
January 2015
December 2014
November 2014
October 2014
September 2014
August 2014
July 2014
June 2014
May 2014
April 2014
March 2014
February 2014
January 2014
December 2013
November 2013
October 2013
September 2013
August 2013
July 2013
June 2013
May 2013
April 2013
March 2013
February 2013
January 2013
December 2012
November 2012
October 2012
September 2012
August 2012
July 2012
June 2012
May 2012
April 2012
March 2012
February 2012
January 2012
December 2011
November 2011
October 2011
September 2011
August 2011
July 2011
June 2011
May 2011
April 2011
March 2011
February 2011
January 2011
December 2010
November 2010
October 2010
September 2010
August 2010
July 2010
June 2010
May 2010
April 2010
March 2010
February 2010
January 2010
December 2009
November 2009
October 2009
September 2009
August 2009
July 2009
June 2009
May 2009
April 2009
March 2009
February 2009
January 2009
December 2008
November 2008
October 2008
September 2008
August 2008
July 2008
June 2008
May 2008
April 2008
March 2008
February 2008
January 2008
December 2007
November 2007
October 2007
September 2007
August 2007
July 2007
June 2007
May 2007
April 2007
March 2007
February 2007
January 2007
2006
2005
2004
2003
2002
2001
2000
1999
1998
1997
1996


JiscMail is a Jisc service.

View our service policies at https://www.jiscmail.ac.uk/policyandsecurity/ and Jisc's privacy policy at https://www.jisc.ac.uk/website/privacy-notice

For help and support help@jisc.ac.uk

Secured by F-Secure Anti-Virus CataList Email List Search Powered by the LISTSERV Email List Manager